Studies lung airflow and mucus plugs with xenon MRI in severe asthma
Uses xenon MRI to examine lung areas beyond mucus plugs in severe asthma.
Plain-language title generated from the registry record
Registry title: Downstream Effects of Airway Mucus Plugs on 129Xenon MRI in Severe Asthma
Key facts
- Where
- Durham, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07139899, who can take part
Where in United States
- Duke University Medical CenterDurham, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bastiaan Driehuys
- Trial code
- NCT07139899
- Record updated
- 20 November 2025
- Original description
In this study, xenon MRI will be used to evaluate regional functional consequences of mucus plugs in the lungs of patients with severe asthma. Mucus plugs will be identified using CT imaging, and xenon MRI will be used to evaluate ventilation and gas exchange impairments in regions of the lungs corresponding to the airways downstream of mucus plugs.Read full original descriptionShow less
Downstream Effects of Airway Mucus Plugs on 129Xenon MRI Following Biologic Therapy
In this study, xenon MRI will be used to evaluate regional functional consequences of mucus plugs in the lungs of patients with severe asthma. Mucus plugs will be identified using CT imaging, and xenon MRI will be used to evaluate ventilation and gas exchange impairments in regions of the lungs corresponding to the airways downstream of mucus plugs.
Inclusion: Adequate completion of informed consent process with written documentation; Patients 18 - 65 years old; Physician diagnosis of asthma for > 1 year; Able to perform reproducible spirometry according to ATS criteria based on clinical PFTs within previous 30 days of enrollment; All racial/ethnic backgrounds may participate; Blood eosinophil count > 300 cells/μL; Smoking history <10 pack years; No smoking history (including vapes, cigar, or marijuana use) in the last 3 months; About to initiate asthma therapy with either dupilumab, tezepelumab, or benralizumab as part of their standard of care.
Exclusion: Respiratory tract infection within the 4 weeks prior to Visit 1; One-time doses such as intra-articular injections require a 4-week washout prior to Visit 1; Asthma-related ER visit within the previous 4 weeks of Visit 1 or at any time while on the study; Significant concomitant medical illness, including (but not limited to) heart disease, cancer, uncontrolled diabetes, other chronic lung diseases (determined by the Investigator.); Participation in an intervention study (including bronchoscopy) or use of investigative drugs within the past 30 days or plans to enroll in such a trial during the study; Conditions that will prohibit MRI scanning determined by the MRI safety screening; Body mass index (BMI) > 30 at Visit 1; Resting O2 saturation <90% with maximum supplemental O2 delivered by nasal cannula; Positive urine pregnancy test at Visit 1 or at any time while on the study; Unable or unlikely to complete study assessments in the opinion of the Investigator; Study intervention poses undue risk to patient in the opinion of the Investigator.